<DOC>
	<DOCNO>NCT01960179</DOCNO>
	<brief_summary>Primary Objective : To assess overall safety lixisenatide daily treatment monotherapy 24 52 week patient type 2 diabetes Japan Secondary Objective : To assess effect lixisenatide daily treatment monotherapy 24 52 week : - HbA1c ( Glycated hemoglobin A1c ) reduction ; - Fasting plasma glucose ; - Body weight .</brief_summary>
	<brief_title>Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes</brief_title>
	<detailed_description>- Group 1 : 60 week ± 11 day - Group 2 : 32 week ± 7 day</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus diagnose least 2 month . Not treated antidiabetic drug treat stable dose 1 oral antidiabetic drug ( OAD ) least 3 month prior screen visit . Previous OAD ( ) stop Visit 1.1 wash runin period least 6 week ; Signed write informed consent . Exclusion criterion : At screen age &lt; 20 year ; HbA1c &lt; 7 % &gt; 9.5 % ( patient OAD &lt; 6.5 % &gt; 8.5 % ) ; fast plasma glucose &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) ; Use one OAD within 3 month prior screen ; Use Thiazolidinedione ( TZD ) within 6 month prior screen ; Use insulin within 3 month prior screen ; Note : Short time use ( ≤10 day ) insulin due acute illness surgery ( eg , infectious disease ) allow . Any previous treatment lixisenatide ( eg , participation previous study lixisenatide ) GLP1 receptor agonist ; Type 1 diabetes mellitus Women childbearing potential effective contraceptive method ; Pregnancy lactation ; Laboratory finding time screening : oAmylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) ; ALT &gt; 3 ULN ; Calcitonin ≥20 pg/mL ( 5.9 pmol/L ) ; Positive serum pregnancy test woman childbearing potential ; History acute chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease ; Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( eg , multiple endocrine neoplasia syndrome ) ; Allergic reaction metacresol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>